Published in Medical Letter on the CDC and FDA, October 18th, 2009
Mr. Billingsley highlighted the sea change in cancer treatment coming from the immunotherapy sector, which was validated by Dendreon's (DNDN) positive FDA announcement and 1,000% stock rise in March 2009. Both Dendreon, for prostate cancer, and Mentor Capital, for breast...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.